

(b) a solubilizing compound comprising a guanidinium group, wherein said solubilizing compound is present in said composition in an amount sufficient to make said IGF-I soluble at a concentration of at least about 12 mg/ml when said composition is at a temperature of about 4°C.

~~22~~ 86. The composition of claim ~~85~~²¹, wherein said solubilizing compound is guanidine hydrochloride.

~~23~~ 87. The composition of claim ~~85~~²¹, wherein said solubilizing compound is arginine.

~~24~~ 88. The composition of claim ~~87~~²³, wherein said arginine is present in a molar concentration range from about 10 mM to about 1 M.

~~25~~ 89. The composition of claim ~~86~~²⁴, wherein said arginine is present in a molar concentration range from about 15 mM to about 500 mM.

~~26~~ 90. The composition of claim ~~89~~²⁵, wherein said arginine is present in a molar concentration range from about 20 mM to about 200 mM.

~~27~~ 91. The composition of claim ~~87~~²³, wherein said pH is in a range from about pH 5.5 to about pH 9.0.

~~28~~ 92. The composition of claim ~~91~~²⁷, wherein said pH is in a range from about pH 5.7 to about pH 6.3.

~~29~~ 93. The composition of claim ~~92~~²⁸, wherein said pH is about pH 6.0.

GAS 30 23
94. The composition of claim 87, wherein said IGF-I is present in said composition at a concentration of about 12 mg/ml to about 200 mg/ml.

31 30
95. The composition of claim 94, wherein said IGF-I is present in said composition at a concentration of about 15 mg/ml to about 200 mg/ml.

32 31
96. The composition of claim 95, wherein said IGF-I is present in said composition at a concentration of about 25 mg/ml to about 200 mg/ml.

C1 33 21
97. The composition of claim 85, wherein said composition comprises sodium chloride at a molar concentration of about 150 mM.

SUB F 57 34 21
98. The composition of claim 85 comprising a buffer selected from the group consisting of a glutaric acid buffer, a maleic acid buffer, a succinic acid buffer, a citric acid buffer, imidazole, and a histidine buffer.

99. A composition comprising:
(a) biologically active human insulin-like growth factor-1 (IGF-I), wherein said IGF-I is present at a concentration of at least about 12 mg/ml when said composition is at a temperature of about 4°C;
(b) a solubilizing compound selected from the group consisting of arginine and guanidine hydrochloride; and
(c) a buffer such that the composition has a pH of about pH 5.5 to about pH 9.0.

36 35
100. The composition of claim 99, further comprising sodium chloride at a molar concentration of about 150 mM.

(S) 101. A composition having a pH of at least about pH 5.5, wherein said composition comprises:

- (a) biologically active human insulin-like growth factor-1 (IGF-I), wherein said IGF-I is present at a concentration of at least about 12 mg/ml when said composition is at a temperature of about 4°C; and
- (b) arginine in an amount sufficient to make said IGF-I soluble at a concentration of at least about 12 mg/ml when said composition is at a temperature of about 4°C.

C1 102. The composition of claim 101, wherein said arginine is present in a molar concentration range from about 10 mM to about 1 M.

103. The composition of claim 102, wherein said arginine is present in a molar concentration range from about 15 mM to about 500 mM.

104. The composition of claim 103, wherein said arginine is present in a molar concentration range from about 20 mM to about 200 mM.

105. The composition of claim 104, wherein said pH is in a range from about pH 5.5 to about pH 9.0.

106. The composition of claim 105, wherein said pH is in a range from about pH 5.7 to about pH 6.3.

107. The composition of claim 106, wherein said pH is about pH 6.0.

108. The composition of claim 101, wherein said IGF-I is present in said composition at a concentration of about 12 mg/ml to about 200 mg/ml.